EUVIMEDEUVIMED entdecken
Kommentar

Diferencias clínicas entre la amiloidosis cardiaca por transtirretina y la cardiopatía hipertensiva

Ignacio Gallo-Fernández, José López-Aguilera, Rafael González-Manzanares, Cristina Pericet-Rodriguez, Manuel Jesús Carmona-Rico, Jorge Perea-Armijo, Juan Carlos Castillo-Domínguez, Manuel Anguita-Sánchez, en representación del Grupo de Trabajo de Insuficiencia Cardiaca del Hospital Reina Sofía

Medicina Clínica · 2024-03 · 162 (5) · 205-212

DOI: 10.1016/j.medcli.2023.10.006 ↗

Kurz gefasst

Kommentar in der Zeitschrift Medicina Clínica, 2024-03. Verfasst von Ignacio Gallo-Fernández und 8 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, España; Instituto de Investigación Biomédica …. Hauptthemen laut MEDLINE: Heart Failure, Amyloid Neuropathies, Familial, Atrial Fibrillation, Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: A significant percentage of patients eventually diagnosed with cardiac transthyretin amyloidosis (TTRA) was previously diagnosed with hypertensive heart disease (HHD), since both conditions usually present with heart failure (HF) with preserved ejection fraction (HFpEF) and ventricular hypertrophy. Our objectives were to evaluate the clinical, electrocardiographic and echocardiographic differences, and to analyse whether there exists a differential prognosis between these two nosological entities. MATERIALS AND METHODS: We retrospectively included all patients with HHD for whom a cardiac scintigraphy with 99mTc-diphosphonate (GDPD) and a free light chains test in blood and urine were ordered for ATTR screening in our centre, in the period between 2016 and 2021. Those diagnosed with other types of amyloidosis were excluded from the analysis. RESULTS: A total of 72 patients were analyzed: 33 were finally diagnosed with TTRA and 39 with CHTA. Patients with TTRA had higher levels of ultrasensitive troponin I (TnI-US) and N-terminal brain natriuretic propeptide (NT-ProBNP); in electrocardiography (ECG) they presented a pseudo-infarction pattern more frequently as well as conduction disturbances; in echocardiography (TTE) they presented a higher degree of ventricular hypertrophy, left ventricular dysfunction and worse diastolic function parameters, with elevated filling pressures. In the 4-year follow-up, the ATTR group showed greater need for pacemaker (PCM), with no evidence regarding mortality, development of atrial fibrillation (AF), or more admissions for heart failure (HF). CONCLUSIONS: In our series, patients with TTRA showed clinical, electrocardiographic and echocardiographic differences compared to patients with HHD, with increased risk of need for PCM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureAmyloid Neuropathies, FamilialAtrial FibrillationHypertensionCardiomyopathiesHumansRetrospective StudiesPrealbuminStroke Volume

Stichwörter der Autor:innen

Amiloidosis cardiaca por transtirretinaCardiac amyloidosisCardiopatía hipertensivaHeart failureHypertensive heart diseaseInsuficiencia cardiacaMarcapasosPacemakerPrognosisPronóstico

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, España; Instituto de Investigación Biomédica de Córdoba, IMIBIC, Córdoba, España.
  • Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, España; Instituto de Investigación Biomédica de Córdoba, IMIBIC, Córdoba, España. Electronic address: mircardjla@gm…
  • Universidad de Córdoba, Córdoba, España.
  • Unidad de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, España; Instituto de Investigación Biomédica de Córdoba, IMIBIC, Córdoba, España; Universidad de Córdoba, Córdoba,…

Zitieren

APA

Gallo-Fernández, I., López-Aguilera, J., González-Manzanares, R., Pericet-Rodriguez, C., Carmona-Rico, M. J., Perea-Armijo, J., Castillo-Domínguez, J. C., Anguita-Sánchez, M., & en representación del Grupo de Trabajo de Insuficiencia Cardiaca del Hospital Reina Sofía (2024). Diferencias clínicas entre la amiloidosis cardiaca por transtirretina y la cardiopatía hipertensiva. Medicina Clínica, 162(5), 205-212. https://doi.org/10.1016/j.medcli.2023.10.006

Vancouver

Gallo-Fernández I, López-Aguilera J, González-Manzanares R, Pericet-Rodriguez C, Carmona-Rico MJ, Perea-Armijo J, et al. Diferencias clínicas entre la amiloidosis cardiaca por transtirretina y la cardiopatía hipertensiva. Medicina Clínica. 2024;162(5):205-212. doi:10.1016/j.medcli.2023.10.006

BibTeX
@article{GalloFernndez2024,
  author = {Gallo-Fernández, Ignacio and López-Aguilera, José and González-Manzanares, Rafael and Pericet-Rodriguez, Cristina and Carmona-Rico, Manuel Jesús and Perea-Armijo, Jorge and Castillo-Domínguez, Juan Carlos and Anguita-Sánchez, Manuel and en representación del Grupo de Trabajo de Insuficiencia Cardiaca del Hospital Reina Sofía, en representación del Grupo de Trabajo de Insuficiencia Cardiaca del Hospital Reina Sofía},
  title = {Diferencias clínicas entre la amiloidosis cardiaca por transtirretina y la cardiopatía hipertensiva},
  journal = {Medicina Clínica},
  year = {2024},
  volume = {162},
  number = {5},
  pages = {205--212},
  doi = {10.1016/j.medcli.2023.10.006}
}
Kostenlos starten →